121 related articles for article (PubMed ID: 21937854)
1. Biotransformation of (-)-camphor by Salmonella typhimurium OY1002/2A6 expressing human CYP2A6 and NADPH-P450 reductase.
Nakahashi H; Miyazawa M
J Oleo Sci; 2011; 60(10):545-8. PubMed ID: 21937854
[TBL] [Abstract][Full Text] [Related]
2. Biotransformation of (+)-fenchone by Salmonella typhimurium OY1002/2A6 expressing human CYP2A6 and NADPH-P450 reductase.
Nakahashi H; Yagi N; Miyazawa M
J Oleo Sci; 2013; 62(5):293-6. PubMed ID: 23648403
[TBL] [Abstract][Full Text] [Related]
3. Development of a Salmonella tester strain sensitive to promutagenic N-nitrosamines: expression of recombinant CYP2A6 and human NADPH-cytochrome P450 reductase in S. typhimurium YG7108.
Kushida H; Fujita K; Suzuki A; Yamada M; Nohmi T; Kamataki T
Mutat Res; 2000 Nov; 471(1-2):135-43. PubMed ID: 11080669
[TBL] [Abstract][Full Text] [Related]
4. Role of human cytochrome P450 (CYP) in the metabolic activation of N-alkylnitrosamines: application of genetically engineered Salmonella typhimurium YG7108 expressing each form of CYP together with human NADPH-cytochrome P450 reductase.
Fujita K; Kamataki T
Mutat Res; 2001 Nov; 483(1-2):35-41. PubMed ID: 11600130
[TBL] [Abstract][Full Text] [Related]
5. New compounds, 6-hydroxykarahanaenone and 10-hydroxykarahanaenone, from biotransformation of karahanaenone by CYP2A6.
Nakahashi H; Yagi N; Miyazawa M
J Asian Nat Prod Res; 2014; 16(9):936-40. PubMed ID: 25082308
[TBL] [Abstract][Full Text] [Related]
6. Metabolic activation of N-alkylnitrosamines in genetically engineered Salmonella typhimurium expressing CYP2E1 or CYP2A6 together with human NADPH-cytochrome P450 reductase.
Kushida H; Fujita K; Suzuki A; Yamada M; Endo T; Nohmi T; Kamataki T
Carcinogenesis; 2000 Jun; 21(6):1227-32. PubMed ID: 10837014
[TBL] [Abstract][Full Text] [Related]
7. Metabolic activation of heterocyclic amines and other procarcinogens in Salmonella typhimurium umu tester strains expressing human cytochrome P4501A1, 1A2, 1B1, 2C9, 2D6, 2E1, and 3A4 and human NADPH-P450 reductase and bacterial O-acetyltransferase.
Oda Y; Aryal P; Terashita T; Gillam EM; Guengerich FP; Shimada T
Mutat Res; 2001 May; 492(1-2):81-90. PubMed ID: 11377247
[TBL] [Abstract][Full Text] [Related]
8. In vitro metabolism of (-)-camphor using human liver microsomes and CYP2A6.
Gyoubu K; Miyazawa M
Biol Pharm Bull; 2007 Feb; 30(2):230-3. PubMed ID: 17268056
[TBL] [Abstract][Full Text] [Related]
9. Genotoxic activation of benzophenone and its two metabolites by human cytochrome P450s in SOS/umu assay.
Takemoto K; Yamazaki H; Nakajima M; Yokoi T
Mutat Res; 2002 Aug; 519(1-2):199-204. PubMed ID: 12160905
[TBL] [Abstract][Full Text] [Related]
10. The stimulatory role of human cytochrome b5 in the bioactivation activities of human CYP1A2, 2A6 and 2E1: a new cell expression system to study cytochrome P450 mediated biotransformation.
Duarte MP; Palma BB; Gilep AA; Laires A; Oliveira JS; Usanov SA; Rueff J; Kranendonk M
Mutagenesis; 2005 Mar; 20(2):93-100. PubMed ID: 15728263
[TBL] [Abstract][Full Text] [Related]
11. Use of genetically engineered Salmonella typhimurium OY1002/1A2 strain coexpressing human cytochrome P450 1A2 and NADPH-cytochrome P450 reductase and bacterial O-acetyltransferase in SOS/umu assay.
Aryal P; Terashita T; Guengerich FP; Shimada T; Oda Y
Environ Mol Mutagen; 2000; 36(2):121-6. PubMed ID: 11013410
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of 7-ethoxycoumarin, safrole, flavanone and hydroxyflavanone by cytochrome P450 2A6 variants.
Uno T; Obe Y; Ogura C; Goto T; Yamamoto K; Nakamura M; Kanamaru K; Yamagata H; Imaishi H
Biopharm Drug Dispos; 2013 Mar; 34(2):87-97. PubMed ID: 23112005
[TBL] [Abstract][Full Text] [Related]
13. Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP.
Kamataki T; Fujita K; Nakayama K; Yamazaki Y; Miyamoto M; Ariyoshi N
Drug Metab Rev; 2002 Aug; 34(3):667-76. PubMed ID: 12214673
[TBL] [Abstract][Full Text] [Related]
14. Roles of human CYP2A6 and rat CYP2B1 in the oxidation of (+)-fenchol by liver microsomes.
Miyazawa M; Gyoubu K
Xenobiotica; 2007 Sep; 37(9):943-53. PubMed ID: 17992728
[TBL] [Abstract][Full Text] [Related]
15. Predicting the mutagenicity of tobacco-related N-nitrosamines in humans using 11 strains of Salmonella typhimurium YG7108, each coexpressing a form of human cytochrome P450 along with NADPH-cytochrome P450 reductase.
Fujita K; Kamataki T
Environ Mol Mutagen; 2001; 38(4):339-46. PubMed ID: 11774366
[TBL] [Abstract][Full Text] [Related]
16. Metabolic activation of carcinogenic 1-nitropyrene by human cytochrome P450 1B1 in Salmonella typhimurium strain expressing an O-acetyltransferase in SOS/umu assay.
Hatanaka N; Yamazaki H; Oda Y; Guengerich FP; Nakajima M; Yokoi T
Mutat Res; 2001 Oct; 497(1-2):223-33. PubMed ID: 11525925
[TBL] [Abstract][Full Text] [Related]
17. Construction of Salmonella typhimurium YG7108 strains, each coexpressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase.
Fujita K; Nakayama K; Yamazaki Y; Tsuruma K; Yamada M; Nohmi T; Kamataki T
Environ Mol Mutagen; 2001; 38(4):329-38. PubMed ID: 11774365
[TBL] [Abstract][Full Text] [Related]
18. Mutagenic activation of betel quid-specific N-nitrosamines catalyzed by human cytochrome P450 coexpressed with NADPH-cytochrome P450 reductase in Salmonella typhimurium YG7108.
Miyazaki M; Sugawara E; Yoshimura T; Yamazaki H; Kamataki T
Mutat Res; 2005 Mar; 581(1-2):165-71. PubMed ID: 15725615
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphism of CYP2A6 in relation to cancer.
Kamataki T; Nunoya K; Sakai Y; Kushida H; Fujita K
Mutat Res; 1999 Jul; 428(1-2):125-30. PubMed ID: 10517986
[TBL] [Abstract][Full Text] [Related]
20. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen.
Koenigs LL; Peter RM; Thompson SJ; Rettie AE; Trager WF
Drug Metab Dispos; 1997 Dec; 25(12):1407-15. PubMed ID: 9394031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
